Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Peter R. Galle, MD, PhD, Mainz University Medical Center
home
Articles
Evolving HCC Treatment Landscape: Combination Therapy
October 30th 2020
Developing Trial Regimens for Chinese Populations
October 30th 2020
High AFP as Deciding Factor for Treatment
October 30th 2020
Immunotherapy Monotherapy in Later-Line Setting
October 30th 2020
Second-Line Options After IMbrave150 Regimen
October 30th 2020
Promising Ongoing Frontline Trials
October 30th 2020
Importance of Endoscopy in Newly Diagnosed HCC
October 30th 2020
NCCN Guidelines: Nivolumab in Frontline Setting
October 30th 2020
Choosing a Frontline Therapy
October 30th 2020
Optimal HCC Frontline Treatments
October 30th 2020
The TACE Approach for Intermediate-Stage Disease
October 30th 2020
The BCLC Staging System
October 30th 2020
Screening Vs Diagnosis: Assessing Liver Function
October 30th 2020
The Complexity of HCC Multidisciplinary Management
October 30th 2020
Emerging Therapies for HCC Management
June 29th 2020
Metastatic HCC Unmet Needs
June 29th 2020
I/O Second-Line Treatment
June 29th 2020
REACH and REACH2 Trial Overview
June 29th 2020
Second-Line Therapy: Monoclonal Antibody
June 29th 2020
Second-Line Sequencing After IMbrave150 Regimen
June 29th 2020
NEXT PAGE
<
1
2
>
PREVIOUS PAGE